Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 11;402(10414):1788-1801.
doi: 10.1016/S0140-6736(23)01289-8. Epub 2023 Sep 21.

Glaucoma: now and beyond

Affiliations
Review

Glaucoma: now and beyond

Hari Jayaram et al. Lancet. .

Abstract

The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery. Although modern surgical innovations aim to be less invasive, many have been introduced with little supporting evidence from randomised controlled trials. Many cases remain undiagnosed until the advanced stages of disease due to the limitations of screening and poor access to opportunistic case finding. Future research aims to generate evidence for intraocular pressure-independent neuroprotective treatments, personalised treatment through genetic risk profiling, and exploration of potential advanced cellular and gene therapies.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests HJ has consulted for Allergan, Ivantis, Scope Ophthalmics, and Rebio; received honoraria for lectures and educational events from Allergan, Laboratoires Théa, and Santen; received support to attend meetings from Allergan; participated on an Advisory Board for Allergan; and has been supported (contribution to salary) by the Moorfields Eye Charity. MK is employed by Copenhagen University Hospital and the University of Copenhagen, and has received funding from the Synoptik Foundation, the Velux Foundation, and Fight for Sight, Denmark. DSF receives institutional grant support from Genentech and the US NIH; has received honoraria for lectures from Laboratoires Théa and Bausch and Lomb; has received support to attend meetings from Laboratoires Théa; is a member of the board of directors of Orbis International; and receives funding from the National Eye Institute and the Harvard Catalyst. GG has received unrestricted research grants from Laboratoires Théa and Santen; has consulted for Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, and Laboratoires Théa; has received support for attending meetings from Ivantis and Laboratoires Théa; and is a clinical advisor to the Patient Advocacy Group of Glaucoma UK. GG is employed by UCL and has been supported by grants from the National Institute for Health Research (HTA 09/104/40), Moorfields Eye Charity, British Council to Prevent Blindness, Fight For Sight, and the International Glaucoma Association (now known as Glaucoma UK).

Similar articles

Cited by

Publication types

LinkOut - more resources